Viking Therapeutics amends bylaws for universal proxy rules and enhanced disclosure

Viking Therapeutics, Inc.

Board approved amended and restated bylaws effective May 9, 2023.
Amendments require stockholders nominating directors to comply with SEC Rule 14a-19 universal proxy rules.
Enhanced disclosure requirements for director nominations and business proposals by stockholders.
Stockholders soliciting proxies must use a proxy card color other than white; white reserved for Board.
Eliminated requirement to make stockholder list available during meetings, consistent with Delaware law.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Viking Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, including compliance with Rule 14a-19, enhanced disclosure requirements, and other conforming changes (effective 2023-05-09).

Change: bylaw amendment
Effective: 2023-05-09

Exact text from the filing

On May 9, 2023, the Board of Directors (the “Board”) of Viking Therapeutics, Inc. (the “Company”) approved and adopted an amendment and restatement of the Company’s amended and restated bylaws (as so amended and restated, the “Amended and Restated Bylaws”), effective as of such date.

View on SEC.gov

Browse all governance changes →

Viking Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021359

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.